Skip to main content
Medicine 3% exam weight

Purpose of the SFDA classification framework

Part of the Saudi GP Board study roadmap. Medicine topic medici-014 of Medicine.

→ See in Roadmap Saudi GP Board Study Plans Build 1-Month Plan
By Last updated 3% exam weight

Purpose of the SFDA classification framework

🟢 Lite — Quick Review (1h–1d)

Rapid summary for last-minute revision before your exam.

Topic 14 in the Saudi GP Board (SCFHS) Medicine blueprint carries a 3% item weight, meaning roughly 3 of every 100 MCQs on the GP licensing exam test this subdomain. The candidate must apply SFDA product classification logic for products whose regulatory category is not immediately obvious from their primary composition — the so-called borderline and combination products encountered in general practice.

Product classDecision ruleGP exam implication
Borderline productDetermined by intended purpose, claimed action, and pharmacological/immunological/metabolic profileClassify before prescribing or advising
Combination productAssessed by primary mode of action (drug vs. device vs. biologic)Determines SFDA review pathway
Drug-device combinationDrug exerts principal action, device delivers itRegulated predominantly as a medicinal product

High-yield pointers: (1) Route of administration alone does not classify a product; (2) A borderline cosmetic-drug is regulated as a drug if it alters physiological function; (3) Combination products with a chemical drug PMOA follow SFDA drug assessment.

🟡 Standard — Regular Study (2d–2mo)

Standard content for students with a few days to months.

Purpose of the SFDA classification framework

The Saudi Food and Drug Authority (SFDA) publishes borderline and combination product classification guides so that manufacturers, importers, and clinicians can determine which regulatory pathway applies. The Saudi GP Board tests this because every prescription, patient query about a supplement, or adverse-event report can hinge on knowing whether a product is regulated as a medicinal product, a medical device, a biologic, or a cosmetic.

Borderline vs. Combination products

A borderline product sits at the edge of two or more regulatory categories — for example, a vitamin injection, an herbal preparation with systemic claims, or a sunscreen with anti-ager claims. Classification rests on the product’s composition, pharmacological properties, and intended purpose as stated in the label and SmPC.

A combination product deliberately merges components from more than one category. Examples include prefilled drug-eluting stents (drug-device), monoclonal antibodies conjugated to radioisotopes (biologic-drug), or scaffolds seeded with living cells (device-biologic).

The “primary mode of action” rule

When a combination product crosses categories, the SFDA assigns the lead regulator based on which component contributes the principal intended action. If a chemical drug drives the therapeutic effect and a device merely delivers it, the SFDA classifies the product as a medicinal product and routes it through drug assessment.

GP exam question patterns

  • A clinical vignette describing a product (e.g., nicotine patch, insulin pump, hyaluronic filler) asks the candidate to pick the SFDA regulatory class.
  • Assertion–reason stems test whether route, composition, or claim drives classification.
  • Prescribing scenarios present a borderline cosmetic and ask whether it requires a drug marketing authorisation.

🔴 Extended — Deep Study (3mo+)

Comprehensive coverage for students on a longer study timeline.

Worked classification walk-through

Product: Hyaluronic acid dermal filler supplied in a prefilled syringe with an integrated microneedle applicator. Question: SFDA regulatory category?

  1. Composition check: Cross-linked hyaluronic acid gel.
  2. Intended purpose: Volumetric correction of facial wrinkles, lasting 6–12 months.
  3. Mechanism: Hyaluronic acid integrates into dermal tissue and attracts water, producing a structural change.
  4. Decision: Because the principal intended action is achieved by a substance acting pharmacologically on the body, the product is regulated as a medicinal product despite the device-style applicator. The microneedle is ancillary.

Edge cases and traps

  • Cosmetic-drug hybrids (anti-dandruff shampoos with anti-fungal claims) move from cosmetic to drug regulation once a physiological claim is made.
  • Companion diagnostics paired with a biologic require joint review.
  • Software as a Medical Device (SaMD) that drives a drug delivery system inherits the combination classification.

Common candidate errors

  • Treating route of administration as the classifier — transdermal drug-device combinations are still drugs.
  • Treating dosage form as the classifier — a lozenge with vitamin claims can still be a borderline product if no disease claim is made.
  • Confusing the SFDA with the Saudi MoH device licensing pathway.

Practice prompts

  1. A patient brings an imported supplement labelled for “liver detoxification.” Classify and justify the next GP action.
  2. A microneedle patch delivers a peptide vaccine. Identify the SFDA lead reviewer pathway and the regulation that supports it.

Continue your study

Content adapted based on your selected roadmap duration. Switch tiers using the selector above.

Sources & verification